Hims & Hers adds three new weight loss drugs to its platform

Hims & Hers added three new weight loss drugs to its platform: Eli Lilly’s Zepbound, Mounjaro, and generic liraglutide, stimulating the company’s stock price to rise 5% on Tuesday.

All three new drugs belong to the GLP-1 receptor agonist class of weight loss drugs. Hims & Hers launched its weight loss program at the end of 2023, but its GLP-1 drugs are constantly adjusting due to changes in the supply and regulatory environment. Previously, the company offered a combination of semaglutide, but Hims & Hers had to stop offering such drugs because the U.S. Food and Drug Administration announced that the shortage of semaglutide injections had been resolved.

Currently, the monthly cost of Zepbound and Mounjaro on the Hims & Hers platform is $1,899, while the monthly cost of generic liraglutide is $299. Although liraglutide is cheaper, it requires daily injections and may not be as effective as other GLP-1 drugs. The company said it will continue to expand its weight loss products in the future to provide a more comprehensive and personalized experience.